Healthcare >> CEO Interviews >> March 15, 1999
K. MICHAEL FORREST, is currently President and Chief Executive Officer
of Cellegy Pharmaceuticals, Inc., a publicly traded biopharmaceutical
company that specializes in innovative approaches to the topical
administration of drugs. He has recently served as President and Chief
Executive Officer of Mercator Genetics, a venture capital backed
genomics company focused on positional cloning of monogenic and
polygenic disease genes. He has over 27 years of experience leading
pharmaceutical and biotechnical companies. He received a B.S. degree in
Business Administration from Georgetown University in 1972. From 1968
through 1980 Mr. Forrest worked for Pfizer Inc., serving a variety of
management positions in overseas markets. From 1980 through 1991, Mr.
Forrest worked for the American Cyanamid Company. From 1986 through
1988, he served as Vice President of Lederle Laboratories in Wayne, New
Jersey and from 1989 to 1991 he served as Vice President of Lederle
International. From 1991 through 1994 he served as President and Chief
Executive Officer of Transkaryotic Therapies, Inc., a gene activation
and ex-vivo gene therapy company located in Cambridge, Massachusetts.
Mr. Forrest also currently serves as Director of AlphaGene Inc., a
private functional genomics company. Profile
Pharmaceuticals, your history and activities.
Mr. Forrest: Cellegy is a company that was formed in the late 1980s by
